Skip to content
type1.science

Dexcom G7 15-Day

Dexcom

What it is

An adult-only version of G7 with 15-day wear, a 12-hour grace period and a 60-minute warm-up under US labeling. It is commercially available in the US; Canadian authorization and a September 2026 Japanese approval announcement do not by themselves establish local sales.

Editorial review: .

Most recent recorded citation date: 2026-09-14. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Available nowRegulator-approvedcgm

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
Benefit or performance
Accuracy: The Dexcom-sponsored study reported 8.0% MARD in 130 adults using 20,310 in-range pairs. This does not establish superiority over standard G7 in a separate study.[1]
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the full discussion and original sources for follow-up duration and study limitations.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Score limitations. Scores are editorial judgments. The 8.0% MARD comes from a separate study, not a head-to-head advantage over standard G7. No distinct marketed-version lag estimate was established here. Sensor survival depends on the analysis used, and nominal wear is not a guarantee that every sensor lasts 15 days.

Default calculation: 85 × 20 + 65 × 15 + 88 × 15 + 88 × 10 + 90 × 10 + 80 × 10 + 80 × 10 + 0 × 5 + 50 × 5 = 7625; divide by total weight 100. Unrounded weighted result: 76.25.

Accuracy85

The Dexcom-sponsored study reported 8.0% MARD in 130 adults using 20,310 in-range pairs. This does not establish superiority over standard G7 in a separate study.[1]

Low lag65

Measures interstitial glucose. A numerical lag estimate for the marketed 15 Day version was not established in this review; this retained editorial score is not a measured delay.[4]

Interoperability88

Current US guidance lists iLet, Omnipod 5, Tandem t:slim X2 and Tandem Mobi for adults 18+. Check system software and compatible sensor/Pod packaging.[8]

Sensor lifespan88

15 days plus a 12-hour grace period. FDA reports a 73.9% Kaplan–Meier survival estimate across 131 sensors through day 15; this is not a simple hardware-failure percentage.[2]

No calibration90

No routine calibration fingersticks. Meter backup is required for treatment decisions with mismatched symptoms/readings, during warm-up, or without a glucose number or trend arrow.[4]

Alerts & prediction80

Configurable alerts include Urgent Low Soon, predicting glucose reaching 55 mg/dL within 20 minutes. This does not guarantee detection of every low.[4]

Form factor80

Same sensor footprint as standard G7, with a 60-minute warm-up instead of under 30 minutes. Sensor water resistance is 2.4 metres for 24 hours.[7]

Ketone sensing0

Measures glucose only; no ketone measurement.[4]

Access & cost50

Commercial US access and coverage pathways are documented. Cost depends on insurance and eligibility; authorization and reimbursement are different questions.[11]

The full picture

The Dexcom G7 15 Day is a separate, longer-wearing G7 version. Its US label is for adults aged 18 and older, with 15 days of wear plus a 12-hour grace period and a 60-minute warm-up. The standard G7 has different age, wear and warm-up specifications. FDA cleared G7 15 Day on 9 April 2025; clearance and commercial launch are different events.43

Accuracy and its limits

The Dexcom-sponsored pivotal paper analyzed 130 adults, including 113 with type 1 diabetes, and 20,310 in-range sensor–laboratory pairs. The first-applied sensor was selected for accuracy analysis when a person wore two. Overall MARD was 8.0%, an average absolute percentage error against the laboratory reference, not a guarantee that each reading is within 8%. Agreement within 15 mg/dL below 70 mg/dL or 15% at/above 70 mg/dL was 87.7%. End-period MARD was 8.9%, so accuracy was not identical throughout wear.1

The study used blinded, postprocessed sensor data and described an investigational 27-minute warm-up, whereas the marketed label specifies 60 minutes. The FDA accuracy tables contain 20,255 pairs, compared with 20,310 in the paper. The reason for this 55-pair difference was not established in the checked primary documents. Results should retain their own dataset and version rather than silently combining the two.12

Low-glucose accuracy is published. In the FDA table grouped by reference glucose, MARD was 12.5% below 54 mg/dL (203 pairs) and 8.2% at 54–69 mg/dL (1,774 pairs). Tables grouped by sensor glucose use different observations and should not be interchanged. Clearance does not guarantee the accuracy of an individual low reading.2

The paper reported no device-related serious events. The study did not establish clinical benefit during pregnancy or with connected pumps.1

The published 8.0% MARD cannot establish superiority over standard G7’s 8.2% arm result because those came from separate studies. The Abbott-funded commercial G7/Libre 3 comparison tested standard G7, not this 15-day version.156

Wear, early endings and meter backup

The FDA review reports 73.9% sensor survival through day 15 using a Kaplan–Meier analysis of 131 sensors. This is not a simple completion fraction from the 130-person accuracy dataset, and its complement is not a 26.1% hardware-failure rate. The analysis included 25 early self-diagnostic shutoffs; scheduled removals and other censoring decisions affect the estimate. A sensitivity analysis was 78.4%, while a separate 95-sensor study estimated 76.0%. These figures describe particular study analyses, not a guarantee for an individual sensor.2

Factory calibration means no routine calibration fingersticks. Use a blood glucose meter for treatment decisions when readings do not match symptoms or expectations, during warm-up, or when the glucose number or trend arrow is missing. Extra wear does not remove the need for a backup plan if a sensor stops early.4

Dexcom’s US provider policy describes replacement of confirmed product failures without a numeric limit, at no cost. The survival result therefore does not support a claim that failures automatically exhaust a fixed replacement allowance; discretionary early removals may be handled differently.12

Water, displays and alerts

The sensor has the same footprint as standard G7 and is water-resistant to 2.4 metres for 24 hours. That rating belongs to the sensor, not the receiver, phone or watch. Direct to Watch needs a compatible phone to pair every new sensor, even though readings can then reach the watch without the phone nearby. Before using a first G7 15 Day sensor, the US guide says to upload receiver data to Dexcom Clarity and update the receiver if prompted.74

Configurable high/low alerts include Urgent Low Soon, predicting glucose reaching 55 mg/dL within 20 minutes. Prediction does not guarantee warning before every low. No separate numerical lag estimate for the marketed G7 15 Day was established in the primary sources checked here; the standard G7 study estimate should not be assigned to this version.45

App correction. FDA lists open Class II corrections Z-2163-2026 and Z-2164-2026 for G7 iOS and watchOS versions 2.9.0–2.11.2, initiated on 14 April and posted on 11 May 2026. The defect can replay older glucose values and trend arrows and delay alerts. Affected users are directed to update to the latest applicable Dexcom app. Both standard G7 and G7 15 Day are included; these notices concern the apps.1314

Receiver speaker recall. A separate FDA notice concerns certain G7 receivers whose speakers may fail to sound low/high alerts. Following Dexcom’s 9 June 2025 update, users should check their receiver at Dexcom’s serial-number checker, request a replacement if affected, and test the speaker whenever charging. A successful sound test does not rule out later failure. The notice lists affected models; it does not cover every G7 receiver.15

What it works with

Current US manufacturer guidance lists iLet, Omnipod 5, Tandem t:slim X2 and Tandem Mobi compatibility for adults 18+. Check the correct pump/software combination; Omnipod 5 requires the compatible G6/G7 Pod version. This does not establish the same availability in every country.8

The open-source Loop project added G7 15 Day support in version 3.10.0, released in January 2026. Generic standard-G7 support in another DIY project is not evidence of 15-day compatibility. Project documentation establishes compatibility scope, not regulatory clearance.9

This sensor measures glucose only, with no ketone measurement. Current US manufacturer guidance allows use during pregnancy for type 1, type 2 or gestational diabetes, subject to its 18+ limit; the pivotal accuracy study excluded pregnant participants.4101

Where it is available

United States: Dexcom announced a 1 December 2025 launch, initially through durable medical equipment providers with retail rollout to follow. Current US product and access information supports commercial availability. Cost and coverage depend on the person’s plan and eligibility; clearance is not a guarantee of reimbursement.1611

Canada: Dexcom announced Health Canada authorization for adults 18+. The current Canadian product page still says coming soon. An exact licence-issue date and a confirmed on-sale date were not established in this review, so authorization is reported separately from commercial access.1718

Japan: Dexcom Japan announced approval 30800BZI00023000 on 14 September 2026 and described public-insurance use for adults 18+ who self-inject insulin. The company release does not establish a shipping date, and a separate PMDA record was not retrieved in this review. Japan is therefore included as an approval development, not yet as confirmed commercial availability on this card.19

This review did not establish G7 15 Day commercial access in the UK, EU or Australia. That is a limit of the checked sources, not proof of worldwide absence.

What is planned

Canadian and Japanese commercial launch timing remains unconfirmed in the sources above. Separately, Dexcom’s May 2026 investor slides describe a future 15-day portfolio baseline, a G8 target of 50% smaller size, and expected late-2027/early-2028 timing. These are future company targets. The slides do not establish G8 ketone functionality or change the specifications of G7 15 Day.20

What's next for this

  • →Canadian commercial availability; the current product page says coming soon. · No confirmed on-sale date in checked sources
  • →Japanese commercial access following Dexcom Japan’s 14 September 2026 approval announcement. · Shipping date not established in the checked release

Sources

  1. [1]
    Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes · Peer-reviewed study · 2025-03-20 — Dexcom-sponsored study: 130 adults, including 113 with type 1 diabetes; 20,310 in-range pairs, MARD 8.0%. Investigational 27-minute warm-up differs from the marketed 60-minute specification. FDA tables use 20,255 pairs; the reason for the 55-pair difference was not established.
  2. [2]
    FDA decision summary K243214 — Dexcom G7 15 Day · Regulatory decision — Pages 6 and 8–9: cleared 60-minute warm-up, 130-person accuracy dataset and 20,255 pairs. Pages 14–15: separate sensor-life analyses, including a Kaplan–Meier estimate of 73.9% across 131 sensors; not a simple failure fraction in the accuracy cohort.
  3. [3]
    FDA clearance letter K243214 — Dexcom G7 15 Day · Regulatory decision · 2025-04-09 — Decision date, distinct from the manufacturer announcement on 10 April 2025.
  4. [4]
    Dexcom G7 15 Day US user guide · Manufacturer — Current US instructions: ages 18+, 60-minute warm-up, 15 days plus 12-hour grace period; meter backup, receiver update, Direct to Watch and sensor water limits. Printed pages 1, 5–6, 38–39, 70–73 and 117 onward.
  5. [5]
    Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes · Peer-reviewed study · 2022-02-21 — Dexcom-funded study. Methods, Results and Tables 2–5: 316 analyzed adults, 619 sensors and 77,774 in-range pairs; site-specific accuracy and estimated lag. This is analytical accuracy, not a trial of clinical benefit.
  6. [6]
    Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems · Peer-reviewed study · 2024-01-08 — Abbott funded, designed, analyzed and interpreted the study. 55 participants contributed YSI data; commercial standard G7 and Libre 3, not G7 15 Day. Only 35 low-YSI pairs per device and one below 54 mg/dL limit hypoglycemia comparisons.
  7. [7]
    Dexcom US comparison of G7 and G7 15 Day · Manufacturer — US product specifications and footnotes: age, wear, warm-up, common sensor footprint and sensor-only water rating. Direct to Watch requires a compatible phone to pair each new sensor.
  8. [8]
    Dexcom US FAQ: upgrading a connected pump to G7 15 Day · Manufacturer — Lists iLet, Omnipod 5, Tandem Mobi and t:slim X2 for adults 18+. Related Omnipod answer requires Pods compatible with both G6/G7; check each system’s current software and labeling.
  9. [9]
    LoopDocs CGM frequently asked questions · Open-source community — Original project documentation: G7 15 Day support added in Loop 3.10.0 in January 2026. Project compatibility is not regulatory clearance.
  10. [10]
    Dexcom US FAQ: use during pregnancy · Manufacturer — Manufacturer guidance permits G7/G7 15 Day during pregnancy for type 1, type 2 or gestational diabetes, subject to product age limits. This is permitted use, not proof of pregnancy-specific clinical benefit.
  11. [11]
    Dexcom US FAQ: how much does G7 cost? · Manufacturer — US access, pharmacy and coverage information; prices depend on coverage and individual eligibility. Medicare eligibility is conditional, not universal reimbursement.
  12. [12]
    Dexcom US provider frequently asked questions — sensor replacement · Manufacturer — Confirmed product failures are replaced without a numeric limit and at no cost under the described policy. This does not mean every discretionary early removal has the same entitlement.
  13. [13]
    FDA Class II correction Z-2163-2026 — G7 iOS app · Regulatory decision · 2026-05-11 — Versions 2.9.0–2.11.2; initiated 14 April 2026. Stale glucose/trend replay and delayed alerts. Includes G7 and G7 15 Day. Follow the update action; this is an app correction.
  14. [14]
    FDA Class II correction Z-2164-2026 — G7 watchOS app · Regulatory decision · 2026-05-11 — Companion watchOS record for versions 2.9.0–2.11.2. The date is FDA posting, not the initiation date.
  15. [15]
    FDA notice: certain Dexcom receivers may miss audible alerts because of speaker failure · Regulatory decision — Affected model/serial scope and June 2025 action update. Check the serial number, request replacement if affected, and test the speaker when charging. A successful test does not rule out later failure.
  16. [16]
    Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States · Manufacturer · 2025-11-20 — Company announcement of a 1 December 2025 US launch, initially through durable medical equipment providers with retail rollout to follow.
  17. [17]
    Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes · Manufacturer · 2026-07-13 — Announcement of authorization for adults 18+, distinct from a commercial launch. A fresh original MDALL licence record was not obtained in this review, so an exact licence-issue date is not asserted.
  18. [18]
    Dexcom Canada G7 15 Day product page · Manufacturer — Current French Canadian page says coming soon. No confirmed on-sale date was established in the checked source.
  19. [19]
    Dexcom Japan announcement of G7 15 Day approval · Manufacturer · 2026-09-14 — Company reports approval 30800BZI00023000 and describes public-insurance use for adults 18+ who self-inject insulin. Original Japanese release read; no separate PMDA record or shipping date was established in this review.
  20. [20]
    Dexcom Investor Day presentation — May 2026 · Manufacturer — Slides 23 and 28–30: future 15-day baseline, G8 target of 50% smaller size and expected late-2027/early-2028 timing. Slide 90 separately describes glucose/potassium work; these slides do not establish G8 ketone functionality. Future company targets are not cleared specifications.